Borg Score Outcomes in Respiratory Compromised Acute Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients Receiving Treatment Via Vibrating Mesh Nebuliser Versus Jet Nebuliser in the Emergency Department
- Conditions
- COPDCOPD Exacerbation
- Interventions
- Device: Vibrating Mesh NebuliserDevice: Jet Nebuliser
- Registration Number
- NCT04181073
- Lead Sponsor
- NHS Greater Clyde and Glasgow
- Brief Summary
The purpose of this study is to compare clinical outcomes in patients with acute COPD treated with a vibrating mesh nebuliser (VMN) versus a current standard jet nebuliser (JN), in the Emergency Department (ED).
Participants will be those who meet the inclusion criteria and have a primary diagnosis of COPD, and consent to take part in the study. Operators will be clinical staff including doctors and nurses who will be trained in the use of the nebulisers.
Delivery of current treatment standards utilising a VMN compared to a JN will improve symptom scores in patients attending ED with COPD exacerbations.
- Detailed Description
This study is a prospective, single-centre, open, randomised study to improve management of acute COPD exacerbation within the Emergency Department. Adults with severe COPD are randomised into 2 groups: vibrating mesh nebuliser or standard jet nebuliser treatment. Salbutamol (5mg) and Ipratropium (0.5mg) will be administered via Aerogen Ultra via valved mask or a standard jet nebuliser via open face mask/. Two further doses of salbutamol to be delivered.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 150
- • Primary presentation with acute exacerbation of COPD
-
• Unable to give valid consent
- Patient unable to speak English
- Patients where alternative diagnosis cannot be excluded
- Known or suspected pneumonia, pneumothorax, pneumomediastinum, pulmonary oedema, vocal cord dysfunction, aspirated foreign body
- Any contraindication to delivering bronchodilators
- Need for immediate intubation , ventilation or non-invasive ventilation
- Pregnant or lactating
- Active palliation considered or expected mortality within 48 hours
- Known background/ comorbid respiratory disease associated with chronic or variable airflow obstruction (significant goitre, central lung tumour or other central airway pathology, bronchiectasis)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Vibrating Mesh Nebuliser Vibrating Mesh Nebuliser Standard therapy of one dose of 0.5 MG Ipratropium and 3 doses of 2.5 MG Salbutamol via Vibrating Mesh Nebuliser Jet Nebuliser Jet Nebuliser Standard therapy of one dose of 0.5 MG Ipratropium and 3 doses of 2.5 MG Salbutamol via Jet Nebuliser
- Primary Outcome Measures
Name Time Method BORG Score 30 minutes post treatment Change in Reported Dyspnoea. Modified BORG dyspnoea scale. 0 (best) min 10 max (worse)
- Secondary Outcome Measures
Name Time Method Completion of Treatment During Emergency Department Admission (typically < 4 hours) Time to complete initial nebulisation therapy in ED
Staff Satisfaction During Emergency Department Admission (typically < 4 hours) Reported ED staff satisfaction from main care giver post treatment. Likert 5 point scale. (0 highly dissatisfied 5 highly satisfied)
Oscillometry 30 minutes post treatment Change of Oscillometry data
Escalation of Care During Emergency Department Admission (typically < 4 hours) Requirement for NIV (non invasive ventilation) / Intubation / further nebulisation
Blood Gas 30 minutes post treatment Change in blood gases post treatment
Trial Locations
- Locations (1)
Emergency Department Queen Elizabeth University Hospital
🇬🇧Glasgow, Scotland, United Kingdom